CD8A and neoplasm: The presence of tumor-specific T-cells is not always conducive with beneficial outcome: An increased pretreatment frequency of MART1- and NY-Eso-1–specific CD8+ T cells in melanoma patients receiving anti–PD-1 treatment was associated with a poorer outcome.